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Abstract
Parkinson disease is a complex disease that has multiple genetic and environmental 
factors. To achieve the early diagnosis and to be able to modify the disease progression, 
efforts are being made to identify individuals at risk. About 20 year ago, an evidence 
of major prevalence of Parkinsonism in patients with Gaucher Disease reported by 
studies worldwide led to the putative involvement of the GBA gene. Nowadays, the 
link from a rare disease with a common disease is well known and it is confirmed that 
mutations in the GBA gene are the most important genetic risk factor. Apart from rare 
mutations, genetic association studied appointed common variants in genes well asso-
ciated with familial cases as LRRK2 and SNCA may also contribute to the increased 
risk for sporadic cases. Other common variants in the MAPT gene were also reported. 
At least, genetic studies have been observed an excessive burden of relevant variants 
in genes with lysosomal function. Thus, a synergistic action of variants in genes that 
codifies proteins involved with the lysosome may be a mean of modulating the risk. 
In this chapter, we review the most robust genetic risk factor and the relevance of 
lysosomal function for Parkinson disease.
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1. Introduction
Parkinson’s disease (PD) is the second most common progressive neurodegen-
erative disease in humans and it is characterized by motor symptoms as muscular 
rigidity, resting tremor, bradykinesia, and postural instability and also by non-
motor symptoms (hyposmia, constipation, depression, dementia, and postural 
hypotension, among others). These symptoms result primarily from the progressive 
loss of the dopaminergic neurons from the pars compacta of the mesencephalic 
substantia nigra and subsequent depletion of the dopamine neurotransmitter in 
the striatum, a central component of the basal ganglia that is responsible for the 
instigation and coordination of movements (Figure 1). The definitive diagnosis of 
PD is difficult being only confirmed with the presence of Lewy bodies, protein-
aceous intracytoplasmic inclusion, in the reminiscent neurons of substantia nigra 
pars compacta and other regions in the brain postmortem analysis [1].
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The etiology is not well understand, but PD is considered a complex disease, 
which counts with multiple genetic and environment factors. The most common 
is the sporadic PD for which the onset generally is late, after 60 years old. There is 
a rare form, the familial PD or monogenic PD (~10% of the cases), for which the 
disease is caused by mutations in a single gene and may present not only a late onset 
but also an earlier onset (below 45 years old) in some cases. Although less frequent, 
the study of monogenic forms of PD and their associated genes helps to understand 
the molecular basis of disease pathogenesis [1, 2].
Segregation studies of mutations in SNCA gene in large families with PD cases 
led to the discovery of the main protein involved in the disease pathogenesis, the 
α-synuclein. Shortly afterwards, postmortem studies in patients’ brains revealed 
that this protein is the major component of Lewy bodies, in both sporadic and 
familial PD patients, reinforcing its important role in the development of PD [2–4]. 
Be it for genetic, environmental or both factors, the fact is that patients’ brains do 
not have the soluble monomeric form of α-synuclein, which is easily degraded by 
lysosomal function, but the insoluble oligomeric forms [5, 6].
Nowadays, efforts have been directed to identify the individuals at risk of mani-
festing PD through clinical, genetic and biochemical markers in order to diagnose 
early and perhaps be possible to modify the progression of disease. For this pur-
pose, genetic variations with the potential to alter the risk for PD have been widely 
researched. Both disease-causing variants and risk variants in genes associated with 
PD vary in frequency depending on ethnic background. Certain genetic variants 
may be a risk factor in an Asian population, but may not be statically significant in 
a European population, for example. The most robust and consistently replicated 
results are appointed to variants in the genes LRRK2, MAPT, SNCA and GBA, the 
last being the major genetic risk factor highlighting the importance of lysosomal 
pathway in the pathogenesis of PD [1–8].
2. Genetic risk factors
More than 20 years ago, Parkinson disease was understood as a disease caused 
by environmental factors only. It was from genetic analyzes in cases of familial PD 
that it was discovered that the genetic factor is also important and may even cause 
certain disease forms. Thus, we have monogenic PD, which can present a pattern 
Figure 1. 
Depigmentation of the substantia nigra (SN) (right panel) compared with control (left panel). Adapted from 
Ref. [1].
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of inheritance defied as autosomal dominant or autosomal recessive. In 1997, the 
discovery of mutations in the SNCA gene as the cause of PD in certain families also 
helped scientists to better understand the etiopathology of this complex disease 
through the association between the duplication and triplication of the SNCA gene 
with altered α-synuclein protein expression and the disease progression. Since 
then, diverse other genes were associated with mutations that cause PD, among 
them the genes LRRK2 and VPS35, that along with SNCA are altered in autosomal 
dominant cases, and PINK1, PARKIN, DJ-1 that are altered in autosomal recessive 
forms [3, 8].
However, the genetics of PD are not simply composed of variants that cause the 
disease. More recently, the focus has been on genetic variants that do not lead to PD 
alone but increase the risk of developing the disease. Among the genetic risk factors 
associated with sporadic PD, rare high-impact variants and common low-impact 
variants have been identified by candidate gene studies and genome-wide associa-
tion studies (GWAS). The complexity of the PD genetic increases even more due to 
several risk variants for PD that are heterogeneous and dependent on the genetic 
background of each population. Genetic variants can be associated with PD in some 
populations, but not in others [8, 9].
Two largest GWAS studies in 2014 and 2017 identified in total 28 independent 
PD-associated risk loci, mainly in SNCA, LRRK2, MAPT and GBA. Genetic risk 
factors are present in several genes involved in metabolic pathways that may be 
directly related to α-synuclein metabolism or involved in processes that affect cel-
lular homeostasis [10, 11].
2.1 SNCA
It is worthy to emphasize the fact that genes that carry rare casual mutations of 
monogenic PD observed in previous family studies are not excluded of the possibil-
ity to also carry common variants that confer risk for developing PD. This is the case 
of LRRK2 and SNCA.
So far, five point mutations (A53T, A30P and E46K) and two copy number 
variation (duplication and triplication) in the gene SNCA are well known to cause 
autosomal dominant PD indistinguishable of sporadic PD, or an early-onset PD 
if the triplication of the gene is present [12]. Recently, single nucleotide polymor-
phisms (SNP) in SCNA were reported in non-coding regions, suggesting that those 
variants play a role in the regulation of the genetic expression through modifica-
tions post-transcriptional as interacting with microRNA or altering alternative 
splicing mechanism [7].
In 1999, the association between REP1, a complex polymorphic microsatellite 
repeat in the promoter region, and PD was pointed out by [13]. Seven years later, 
Maraganore [14] confirmed this association with a larger meta-analysis study using 
more than 5000 samples from 11 sites. Further, functional analysis studies provided 
evidence that the length of alleles affects the protein expression: the 261 bp-long 
risk allele is associated with an upregulation of α-synuclein expression mimick-
ing SNCA locus multiplication, whereas the 259 bp-long protective variant shows 
reduced gene expression [15].
In 2009, Simón-Sánchez et al. [16] used GWAS in a great sample and identified 
additional signals of association with PD from intro 4 to after the 3′ UTR. One year 
later, Mata et al. [17] showed possible association between rs356219 in the 3′ UTR 
region and α-synuclein plasma levels. To definitely ascertain which variants in this 
region alter the risk for PD, more studies are necessary in large and genetically 
diverse samples.
Molecular Medicine
4
2.2 LRRK2
In the region of chromosome 12 is localized the LRRK2 gene where several 
genetic variants have been found; however, segregation in families with monogenic 
PD and case-control studies demonstrated that only seven point variants (R1441G, 
R1441C, R1441H, Y1699C, G2019S, I2020T and N1437H) have enough evidence to 
be defined as cause of PD. This gene encodes a protein of the same name composed 
of domains with kinase activity, GTPase and several domains of interaction with 
other proteins, suggesting that its function changes depending on which proteins 
form complexes, the type of cells and the stage of development. Mutations in 
LRRK2 gene are the most common cause of PD familial cases. The mutation G2019S 
is the most prevalent worldwide, and it is present in 4% of familial PD and is 
associated with an indistinguishable phenotype from the clinical manifestations of 
sporadic PD [12–18].
Besides the prevalence in rare monogenic PD, this mutation can also confer 
risk in the sporadic PD, being found in 1% of the cases. G2019S has a penetrance 
variable, and its carrier’s risk to develop PD depends on age and ethnic background. 
The age-related risk has been estimated to be 28% at age 59, 51% at 69, and 74% at 
79 years. The frequency is higher in North African, Middle Eastern and Ashkenazi 
Jewish PD patients [18, 19].
G2019S is frequent in most populations worldwide, but it is very rare in the 
Asian population where it accounts for less than 1% of LRRK2 mutations. In con-
trast, most common genetic variants SNPs G2385R and R1628P are more frequent 
in Asian populations than in Caucasian populations. Those SNPs are associated 
with an increased risk of 2.2 fold and 1.84 fold to develop PD, respectively [20, 21]. 
Lately, regions close to LRRK2 have been appointed by GWAS as increasing by 1.2 
fold the risk for PD. This fact alerts that the regulation of the gene expression is 
important to develop this disease [8].
Those works reinforce the idea that genes can carry both rare disease-causing 
variants and common variants that increase the risk for PD, as seen in SNCA and 
LRRK2. Additionally, common variants present in those genes enhance the impor-
tance of their proteins’ role in the disease and implicate that there is a common 
neurodegenerative process between sporadic and familial PD.
2.3 MAPT
The gene MAPT is frequently associated with other neurodegenerative diseases 
as Alzheimer disease and frontotemporal dementia (FDT). MAPT encodes for the 
microtubule-associated protein tau, whose role is to regulate microtubule dynamics 
and assemble microtubules into parallel arrays within axons, essential for normal 
axonal transport in neurons. Polymorphisms in this gene have been found to be an 
indisputable risk factor of the synucleinopathy. The H1 and H2 haplotypes rep-
resent two distinct clades of subhaplotypes ensued from an inversion of ∼900 kb 
on chromosome 17q21, spanning the entire MAPT coding region, and are tagged, 
among others, by genotypes at two SNPs: rs9468 and rs1800547 [4–8].
The H1 haplotype and its subhaplotype H1c have been significantly associ-
ated with an increased risk for a number of neurodegenerative diseases. Several 
studies proposed the most common H1 haplotype as susceptibility factor for PD 
with an odds ratio of 1.5. Recent studies that investigated the association between 
H1 and specific PD clinical manifestation also observed the higher prevalence of 
H1 in patients with cognitive defects, as dementia and H1 homozygous PD patients 
showed an increased risk to manifest non-tremor dominant subtype, which is a 
worse clinical prognosis [22, 23].
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The underlying biological mechanisms that link the MAPT locus (and tau 
protein) to neurodegeneration are not yet adequately characterized. Through the 
functional characterization of variants in the MAPT gene, some theories of the tau 
protein effect in PD involve increased tau expression; altered gene splicing promot-
ing aggregation; and altered 4/3 repeated transcript ratio. The emerging concept of 
H1 pathogenicity points to the role of each tau isoforms expressed rather than the 
overall number of transcripts.
According to this model, the H1 haplotype is associated with an underexpression 
of a protective isoform and an overexpression of the detrimental variant, which 
lead to a subtle neuronal dysfunction that accumulates over the years and induces 
or accelerates cellular degeneration [22–24]. However this locus harbors many genes 
and the extended linkage disequilibrium means that the tau protein may be not the 
cause of neurodegeneration and its DNA sequence is just close to the casual locus. 
Thus, while MAPT is a candidate, we cannot be certain that this is the true biologi-
cal mediator of risk [7–16].
Diverse studies identified MAPT locus variants as a risk factor for PD, but it may 
not be true to any population. In the Caucasian population, there was this associa-
tion, while it was absent in the Japanese population. This observation has potential 
implications for the analysis of complex traits across populations such as genetic 
heterogeneity, particularly at minor risk loci, highlighting the power of comparing 
GWAS across different populations [9–16].
Despite having a modest effect (less than 30% of the change in risk), these 
common variants can have a considerable impact when combined. Results from a 
2015 study revealed that patients at an early age of onset of symptoms had a higher 
polygenic combination of risk variants than patients with a late onset. This dem-
onstrates the possible effect of the synergistic value of the changes caused by these 
variants to modulate the PD clinic, such as the age of onset of symptoms [12].
3. GBA: the principal genetic risk factor for Parkinson disease
The GBA gene was initially described in association with a rare lysosomal stor-
age disease (LSD) called Gaucher disease (GD). When mutated in homozygosis, 
depending on the mutation present, the resulting enzyme is malformed or even 
no enzyme is synthesized leading to enzyme glucocerebrosidase (GCase) partial 
or total deficiency and glucosylceramide (GlcCer) accumulation. The symptoms 
are multisystemic, with the brain, spleen, liver and bone marrow being the main 
organs affected. The presence and intensity of those symptoms differ between 
the three types of GD (GD1, GD2 and GD3). The heterozygous individuals do not 
present any clinical manifestation; however, in the last years, this perspective has 
changed [25, 26].
Further a number of studies have recorded the occurrence of parkinsonian 
manifestations in patients with GD and their relatives [27, 28]. In ref. [29] was 
showed that GBA mutations homozygous individuals have 21.4 fold increased 
risk to develop PD with probability of 9–12% to manifest motor symptoms before 
80 years old. Despite being low, this risk is considerably higher than in the same age 
group in general population, 3%. The GBA and PD association was confirmed in 
the Jewish Ashkenazi, which showed a prevalence of GBA mutations in heterozy-
gosis and homozygosis individuals in the PD population that by far outweighs the 
reported prevalence of mutations in other susceptibility genes for PD, as Parkin and 
SNCA [30].
Researchers worldwide have attempted to validate the same association in popu-
lations from many different genetic backgrounds [31–41]. In 2009, an international 
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and multicenter study with a great sample of approximately 5000 PD patients and 
equal number of controls provided the definitive proof found for this association 
with an odds ratio greater than five (OR 5.3) and showed that mutations N370S and 
L444P are the most frequent in this gene. In other words, GBA mutation genes were 
recognized as the major genetic risk factor for PD until now [42].
In addition to alter the risk to manifest the disease, the presence of GBA muta-
tions has also the potential to modify PD phenotype such as age of onset. The 
modulatory effects best described in the literature investigated the association with 
age of onset and declined cognitive. The association to other symptoms and patients 
survival rate has been not yet approached in more detail.
Whether in heterozygosis or in homozygosis individuals (GD patients), the age 
of onset of symptoms apparently occurs earlier than in PD patients without muta-
tions, usually between the fourth and sixth decade of life [28–43]. In relation to 
symptoms is noticeable a cognitive decline earlier in PD patients with GBA muta-
tions (PD-GBA) [26–45]. Dementia is one of the clinical manifestations that most 
affects the patient’s quality of life and it is more frequent in GBA mutation carriers 
than in non-carriers. Longitudinal studies have shown that PD-GBA patients have 
a risk three times higher than patients without GBA mutations to present dementia 
[26, 44, 46]. Neuroimaging exams support this association by showing more expan-
sive synucleinopathy in the neocortical and subcortical areas of PD-GBA patients, 
increasing the risk to dementia, psychosis and postural hypotension [46].
A few studies have evaluated the survival rate, if there is a greater risk of death 
in PD-GBA patients than in those without any mutations. A 2014 study found lower 
survival for the carrier group, but had a weak statistical value [47]. However, in 
2016, a study with the largest sample number ever described replicated the same 
result with powerful statistical significance reinforcing this conclusion. It was 
defined in this study that there is a twice greater risk of mortality among PD-GBA 
patients. One explanation may be the increased presence of non-responsive levo-
dopa motor impairments such as dysphagia and non-motor impairments such as 
orthostatic hypotension in the group of PD-GBA. There was no difference in disease 
duration compared to non-carriers, but patients were significantly younger at the 
time of death [46].
3.1 Genotype-phenotype correlations
Researchers have also observed different GBA mutations having a different 
impact in the clinical manifestations. Mutations generally associated with defined 
neuropathic forms of GD (GD type 2 and 3), such as L444P, are classified as severe 
mutations, while others associated with GD type 1, such as N370S, are classified as 
mild mutations [26–48].
A meta-analysis study included populations from North, Central and South 
America, Western and Eastern Europe, North Africa, Asia and Ashkenazi Jews, and 
its results showed a clear and significant differentiated effect comparing mild and 
severe mutations on the risk of developing PD and the age of onset of symptoms 
not only in Ashkenazi populations, but also worldwide. Severe mutations such as 
L444P confer a three to four times increased risk for its carriers to develop PD and 
are associated with the onset of symptoms 5 years earlier than mild mutations. The 
average age found for severe mutations was 53.1 (±11.2), whereas the average age for 
mild mutations was 58.1 (±10.6) [26].
The type of mutation was also relevant in modulating the cognitive impairments 
of PD patients. Ref. [46] observed that severe mutations conferred a higher risk of 
dementia for its carriers. The risk was three times greater compared to patients with 
mild mutations and five times greater when compared to the risk for PD without 
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GBA mutations. Another longitudinal study with a similar sample number corrobo-
rated with the increased risk of dementia for patients with severe mutations versus 
non-carriers [44]. With regard to other symptoms, motor impairments appear to 
be similar between patients with mild mutations and non-carriers, while those with 
severe mutations appear to be more aggravated and seem to have a higher frequency 
of non-motor symptoms such as psychosis, apathy and postural hypotension [46].
Patients’ survival does not seem to differ when comparing the types of muta-
tions with each other. However, when compared separately with non-carriers, mild 
mutations do not differ statistically from non-carriers, while mortality was shown 
to be greater for carriers of severe mutations than in non-carriers [46].
Due to the discovery and increasing number of proofs supporting the great 
influence of GBA mutations in PD, some authors consider the possibility of reclas-
sifying them from risk factors for agents causing autosomal dominant PD [43, 49].
4. GBA-associated PD in different populations
Given the multifactorial etiology of PD, the different environment and ethnic-
ity of a population may impact in the different results seen among the papers that 
investigated the frequency of GBA mutations in PD patients. Other possible causes 
of this variation can be the use of different techniques and methodologies.
The highest frequencies of mutations of the GBA gene have been found in PD 
patients of Ashkenazi Jewish ancestry, with rates of 13.7–31.3% in comparison with 
4.5–6.2% in control groups [26–28]. The frequencies recorded in PD patients in 
non-Jewish populations representing other populations, such as Italians, Caucasian 
Americans, Greeks, Brazilians, British and Taiwanese, are invariably much lower—
3.5% to 12.0%—while controls from the same populations range from 0% to 5.3% 
[31–41]. Previously, in North Africa, a study found no association between PD and 
mutations of the GBA gene; however, a more recent African study data suggested 
a risk association between mutations in the GBA gene and PD [37]. The lowest rate 
recorded to date was 2.3% in Norwegian PD patients, compared with 1.7% in the 
control [49].
The genetic background can also impact the frequency even within the same 
country. In Brazil, four studies evaluated the association between GBA and PD, with 
variances in frequencies depending on the region (Table 1). The North region had 
twice as many cases of PD patients with GBA mutations (7.4%) compared to the fre-
quencies of the South and Southeast regions (3.5%) with a similar sample number. 
The fact may be explained by the different genetic composition of the North region, 
which, despite also has a European origin, has a higher Amerindian ancestry than 
the Southern Brazil, which is almost exclusively from European ancestry [31–50].
Greek and Italian studies have found significant differences comparing PD 
patients and controls from urban and rural areas, and from the North and South 
regions, respectively. In the Greek study, the frequency of GBA mutations between 
PD patients and controls was statically significant. However, when the cohorts were 
analyzed separately, there was a difference of frequencies. The difference between 
PD patients and controls was statistically significant only in the case of the patients 
of cohort A that is originated from Thessaly, a mainly rural area (p = 0.021, OR 4.2, 
95% CI = 1.14–15.54) and not in the case of cohort B patients, the majority of which 
were residents and/or originated from the greater area of Athens, an urban environ-
ment (p = 0.113, OR 2.5, 95% CI = 0.77–8.42) [34].
In the Italian study, there was a lower frequency of mutations in PD patients 
(11/395, 2.8%) and in controls (1/483, 0.2%) from the Southern region, and the 
most common mutation was p.L444P. Conversely, in the Northern region, the most 
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Studies Population studied PD inclusion 
criteria
Method Mutation 
analyzed
Patients 
mutation 
frequency
Control 
mutation 
frequency
Age of onset GBA mutated 
PD and familiar 
history (FH)
Spitz et al. 
(2007)
65 PD patients and 
267 control subjects 
from Southeastern 
Brazil
Early onset 
(<55 years).
PCR-RFLP, restriction 
endonucleases and 
electrophoresis
N370S and 
L444P
2/65 (3%); 
L444P 2/2 
(100%); 
N370S 0/2 
(0%)
0/267 Patient 1 at 
46 yr old and 
patient 2 at 42 yr 
old
The two patients 
had FH, no 
statistical test was 
used.
Socal et al. 
(2008)
62 PD patients from 
Southern Brazil
All patients 
diagnosed 
were included.
PCR-RFLP, restriction 
endonucleases
N370S, 
L444P and 
IVS2þ1
2/62 (3.5%); 
L444P 1/2 
(50%); N370S 
1/2 (50%)
Not 
informed
Patients with 
mutation 
37 ± 4 yr
Patients without 
mutation 
41.4 ± 10.8 yr
Not informed.
De 
Carvalho 
et al. 
(2012)
347 PD patients and 
341 control subjects 
from Southeastern, 
Midwestern and 
Northern Brazil
All patients 
diagnosed 
were included.
Direct sequencing N370S and 
L444P
13/347 (3.7%); 
L444P 8/13 
(62%); N370S 
5/13 (38%)
0/341 Patients with 
mutation 
49.9 ± 11.3 yr
Patients without 
mutation 
52.5 ± 13.3 yr
Those with FH 
and those without 
FH did not 
present statistical 
significance.
Amaral 
et al. 
(2018)
81 PD patients and 81 
control subjects from 
Northern Brazil
All patients 
diagnosed 
were included.
Amplification of the 
exon 8–exon 11, PCR-RFLP 
for N370S and L444P, 
restriction endonucleases 
and direct sequencing of 
N370S and L444P
N370S and 
L444P
6/81 (7.4%); 
L444P 3/6 
(50%); N370S 
3/6 (50%)
0/81 Patients with 
mutation 
49.6 ± 17.4 yr
Patients without 
55.1 ± 11.6 yr
From the 6 patients, 
2 had FH. No 
statistical test was 
used.
Bold valor are percentage.
Table 1.  
GBA mutation among PD patients in different Brazilian regions.
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frequent genetic defect found was p.N370S and the frequency of mutations in PD 
was 4.5% and 0.63% in controls. Therefore, the difference may be due to a particu-
lar frequency of GBA mutations in regions of Italy or to the sample size [36].
Although the frequency of GBA mutations in populations of PD patients has 
been well characterized worldwide, few data are available on the inverse relation-
ship, that is, the risk of healthy heterozygous for GBA mutations in developing PD, 
since it is not known for sure the degree of influence that this genetic alteration has 
on the onset of the disease.
Anheim M et al. [43] published in 2012 an estimate of the penetration of PD in 
healthy heterozygous people for GBA mutations and reached a value of 7.6%, 13.7%, 
21.4% and 29.7% for 50, 60, 70 and 80 years, respectively, based on a dominance 
model. However, in the same year, [51] found a lower value: 5% for 60 years and 
15% for 80 years of age. Such difference is perhaps due to additional genetic fac-
tors or environmental factors, a fact that emphasizes the possibility of variance of 
the risk of developing PD according to the genetic background of the population. 
Families that have GBA mutations segregation through generations are a group at 
risk for developing PD and should be monitored for a possible early diagnosis to 
have better chances in modifying the disease.
5. Pathogenic mechanisms in PD
α-Synuclein is a key protein in the neuropathogenesis of PD, involved in several 
pathogenic processes. The physiological function of α-synuclein is not well under-
stood, but studies show that it is normally located in presynaptic terminals where 
it binds to lipids and plays the role of regulating in more than one step the traffic of 
synaptic vesicles to be released. As cited above, the insoluble forms (oligomers and 
fibrils) of this protein accumulate and compound the Lewy bodies found in most 
PD patients and also contribute to neuronal cell death [5].
The reason behind this accumulation can be due to increased synthesis or 
decreased degradation (Figure 2). Mutations, as the triplications of the SNCA 
gene, can enhance the production of α-synuclein, while the interaction between the 
oligomers and fibrils formed with other mutant proteins can result in the deficiency 
of certain metabolic pathways and contribute to slowing down α-synuclein prote-
olysis. On the other hand, the initial deficiency of certain metabolic pathway caused 
by mutations in genes, advanced age or environmental factors can also be the trigger 
to accumulate α-synuclein resulting in the insoluble forms. This last theory has been 
Figure 2. 
The proposed physiological and PD-associated pathological functions of α-synuclein in neurons. Adapted from 
Ref. [6].
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reinforced by the confirmed association of diverse genes involved in autophagy, 
endocytosis and lysosomal pathways as the GBA and LRRK2 gene [1–6].
5.1 Lysosomal function-related genes and PD
The endosome-lysosome traffic processes, autophagy and lysosomal deg-
radation, are essential functions for cell homeostasis, especially for neurons. 
The differentiated neurons have to maintain their homeostasis during the aging 
through degradation pathways since they do not divide in the same way as other 
eukaryotic cells. Moreover, cellular and animal models have also shown that the 
process of lysosome-autophagy and ubiquitin-proteasome has its activity reduced 
with natural aging. It may cause the accumulation of proteins whose homeostasis 
depends on those processes, such as α-synuclein. Indeed, the stimulation of degra-
dation by macroautophagy through drugs proved to decrease intracellular levels of 
α-synuclein in experimental models [1–6].
Reciprocally, the accumulation of α-synuclein in the substantia nigra in experi-
mental models leads to a reduction in lysosomal enzymes such as GCase, cathepsin B, 
β-galactosidase and hexosaminidase causing the inhibition of macroautophagy and 
ubiquitin-proteasome processes as a consequence enzyme transport to the lysosome 
interruption through dysfunction of vesicles and endosomes. The result is a vicious 
cycle where α-synuclein degradation mechanisms are inefficient resulting in the 
protein accumulation and it reinforces the inhibition of degradation activity [5–52].
Both GCase deficiency and the accumulation of its substrate (GlcCer) have been 
described to be associated with neurodegeneration (Figure 3). Feany M et al. [53] 
suggested that the connection of the α-synuclein to lipidic membranes would pro-
tect this protein from inadequate and clumped folding. Mutations of the GBA gene 
would alter the lipid composition of the membrane, which would favor a build-up 
of α-synuclein in the cytosol and subsequently in the Lewy bodies. Knockdown 
GBA in neuronal cells or in mouse models impairs α-synuclein clearance, whereas 
increasing glucocerebrosidase activity has the opposite effect, perhaps giving 
support to the loss-of-function theory in which the reduced or absent lysosomal 
enzyme is the trigger to α-synuclein accumulation [54].
Even excluding GBA, there was evidence for a burden damaging alleles in 
association with PD. In 2017, Ref. [55] performed a large study to examine the 
overlap between genes responsible for LSD and PD. More than half of PD cases in 
their cohort harbors one or more putative damaging variants among the 54 LSD 
genes. Specially, risk alleles in the genes SMPD1 (Niemann-Pick type A/B), GALC 
(Krabbe disease), SLC17A5 (Salla disease), ASAH1 (Farber lipogranulomatosis) and 
CTSD (neuronal ceroid lipofuscinosis) have been candidate genes well replicated 
in different studies. SMPD1 and ASAH1, along with GBA, participate in ceramide 
metabolism, and this fact can be evidence of the ceramide-associated process being 
relevant in a scenery of lysosomal dysfunction in PD [10–55].
The genes appointed as risk factor for PD to date explain only a fraction of 
PD heritability, suggesting the involvement of additional loci. Besides, the fact 
that GBA is the major genetic risk factor for PD makes other LSD genes attractive 
candidate risk factors. The results of [55] suggest that many genes that encode lyso-
somal enzymes besides GBA likely contribute to susceptibility for PD in Caucasian 
population.
Not only the lysosomal function is important, but also the previous steps neces-
sary for the vesicle content to reach this organelle. In [10], a GWAS meta-analysis 
study found that PD-associated signals were enriched for autophagy and lysosomal 
function. SCARB2 encodes a membrane protein (LIMP-2) required for correct tar-
geting of GCase enzyme to the lysosome. Independent large GWAS have replicated 
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common risk alleles in this gene. Functional analysis in cellular and animal model 
has shown that the reduction of LIMP-2 impairs the clearance of α-synuclein [55]. 
Those data reinforce that both the malfunction and the absence of the GCase, 
through mutations or impairment in the pathway, can result in α-synuclein 
accumulation.
The protein LRRK2 is complex and can work together with diverse proteins in 
different pathways, but for PD, the most relevant seems to be its endosome-to-lys-
osome trafficking function. Mutations in the kinase domain of the LRRK2 protein, 
such as the most common G2019S, compromise the traffic of the endosomal content 
to the lysosome through accentuated phosphorylation resulting in the dysregulation 
of proteins of the Rab family, responsible to target vesicles to the correct organelle 
membranes, including the lysosome [6–18].
In support of vesicular trafficking to lysosome impairment in PD, in 2009, two 
GWAS collaborative studies examining Caucasian and Asian subjects revealed 
significant risk alleles in PARK16 locus for PD. This locus is a large linkage disequi-
librium block that includes a Rab protein member of a subfamily that is implicated 
in vesicular transport to lysosomes and to lysosome-like organelles, the Rab-7 L1 
(also known as RAB29) [9–16].
Mutations in the VPS35 gene are one of the causes for autosomal dominant 
PD. Its protein is also involved in trafficking to lysosomes as a member of the 
Figure 3. 
The vicious cycle between the GCase and α-synuclein. Decreased glucocerebrosidase increases the lysosomal 
concentrations of glucosylceramide, which increases the formation of soluble α-synuclein oligomers. These 
oligomers also disrupt transport of newly synthesized glucocerebrosidase between the endoplasmic reticulum 
and Golgi apparatus, further compounding the problem. Adapted from reference [52].
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Figure 4. 
Some of the PD-related genes associated with trafficking to the lysosome. Genes that encode intracellular 
trafficking components are associated with common sporadic and familial forms of PD, as well as related 
syndromes that share some of the clinical features of PD. Most of these genes are known to affect trafficking 
to the lysosome in the context of late endosome-to-lysosome pathways, clathrin-dependent endocytosis, 
macroautophagy or mitophagy. Wild-type α-synuclein (blue) can also enter lysosomes through chaperone-
mediated autophagy. Adapted from Ref. [6].
retromer complex, which has the role to regulate the delivery of the protein content 
within endosomes to organelles. Some of the proteins carried by this complex are 
cation-independent mannose-6-phosphate receptors, necessary for the transport 
of lysosomal enzymes to the lysosome. In the dysfunction of the retromer complex, 
the receptors are not returned to the Golgi complex, thus impairing the lysosomal 
function. In addition, mutations in ATP13A2 are a rare cause of recessive juvenile-
onset Parkinsonism and dementia and are associated to lysosomal dysfunction. This 
gene codifies a lysosomal P-type ATPase [1, 6].
Interestingly, potentiated retromer function might suppress the altered traffick-
ing and toxicity that are associated with mutations in LRRK2 or the overexpression 
of α-synuclein85, which suggests a potential therapeutic avenue. This fact empha-
sizes the possibility that different genes can interact with each other influencing the 
lysosomal function and as a consequence modifying the PD progression.
These common and rare risk alleles in ATP13A1, RAB7L1, LRRK2 and VPS35, 
which support a model of partial loss-of-function variants in genes regulating 
lysosomal activity by cellular trafficking, result in an increased vulnerability to 
α-synuclein mechanisms in PD [55]. Ref. [10], the largest GWAS meta-analysis 
study, concluded that PD-associated signals were enriched for autophagy and 
lysosomal function. It replicated the results for GBA and TMEM175 genes, which 
encode a potassium channel involved in the regulation of lysosome and identified 
three novel candidate genes, CTSB (a lysosomal cysteine protease), ATP60A1 (an 
ATPase) and GALC (a lysosomal enzyme).
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Besides GBA, loss-of-function alleles are known as frequent PD risk factors, and 
some of those genes had the functional characterization made by analysis stud-
ies that showed knockout mice manifesting tremor phenotype with cerebral and 
cerebellar atrophy, thus corroborating with lysosome loss-of-function hypothesis to 
be involved with α-synuclein dysfunction and PD pathogenesis [10].
Therefore, advances in genetic and experimental model for PD have illuminated 
an important role for defects in intracellular transport pathways to lysosomes 
(Figure 4). The probability of discovering rare PD disease risk alleles at a single 
locus is low; however, if a set of lysosomal-related genes is investigated in conjunc-
tion, the chance of finding significant genetic variations is increased. Also, the can-
didate genes here appointed need further studies including even larger case–control 
studies and experiments in PD cellular or animal models.
6. Conclusion
Currently, genetic testing for PD is not a routine procedure, being restricted 
only to cases with a positive family history, with early onset or with the presence 
of specific atypical symptoms. In the future with the advance of genetic research, 
however, there is a possibility to use genetic variants to provide a perspective of 
the patient’s clinical evolution. For this purpose, it is important to replicate risk 
variants for PD in large and genetically diverse samples due to the different results 
among populations. Genetic studies need to be a collaboration of the whole world 
to understand the genetics of a complex disease. In addition, candidate genes here 
appointed need further experiments in PD cellular or animal models understand-
ing of the underlying pathology and molecular pathogenesis to provide perhaps 
the basis for the development of new therapies able to target mutated proteins that 
cause impairment in relevant pathways for PD as endosome trafficking, lysosome 
function and autophagy.
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